BR0214364A - Métodos para obter melhorada qualidade dos ossos de um vertebrado e para modular a qualidade dos ossos de um vertebrado, uso de glutamato, derivados de glutamato, ou metabólitos, análogos de glutamato ou misturas dos mesmos, e, método para inibir, prevenir ou aliviar a degradação da estrutura óssoa ou enfraquecimento óssea em um vertebrado - Google Patents

Métodos para obter melhorada qualidade dos ossos de um vertebrado e para modular a qualidade dos ossos de um vertebrado, uso de glutamato, derivados de glutamato, ou metabólitos, análogos de glutamato ou misturas dos mesmos, e, método para inibir, prevenir ou aliviar a degradação da estrutura óssoa ou enfraquecimento óssea em um vertebrado

Info

Publication number
BR0214364A
BR0214364A BR0214364-0A BR0214364A BR0214364A BR 0214364 A BR0214364 A BR 0214364A BR 0214364 A BR0214364 A BR 0214364A BR 0214364 A BR0214364 A BR 0214364A
Authority
BR
Brazil
Prior art keywords
vertebrate
glutamate
bones
quality
bone
Prior art date
Application number
BR0214364-0A
Other languages
English (en)
Inventor
Tadeusz Studzinski
Jose Luis Valverde Piedra
Stefan Pierzynowski
Original Assignee
Essentys Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27354772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0214364(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0104385A external-priority patent/SE520842C2/sv
Application filed by Essentys Ab filed Critical Essentys Ab
Publication of BR0214364A publication Critical patent/BR0214364A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)

Abstract

"MéTODOS PARA OBTER MELHORADA QUALIDADE DOS OSSOS DE UM VERTEBRADO E PARA MODULAR A QUALIDADE DOS OSSOS DE UM VERTEBRADO, USO DE GLUTAMATO, DERIVADOS DE GLUTAMATO, OU METABóLITOS, ANáLOGOS DE GLUTAMATO OU MISTURAS DOS MESMOS, E, MéTODO PARA INIBIR, PREVENIR OU ALIVIAR A DEGRADAçãO DA ESTRUTURA óSSEA OU ENFRAQUECIMENTO óSSEO EM UM VERTEBRADO". Um método para obter uma melhorada qualidade dos ossos em um vertebrado, incluindo mamífero e ave, o método compreendendo a administração a um vertebrado, incluindo mamífero e ave, em uma quantidade suficiente e/ou em uma taxa suficiente para permitir o efeito desejado., glutamato, derivados de glutamato, ou metabólitos, análogos de glutamato ou misturas dos mesmos. Também é contemplado um método para modular a qualidade dos ossos em um vertebrado, incluindo mamífero e ave, compreendendo a administração ao vertebrado, incluindo mamífero e ave, em necessidade do mesmo, de glutamato, derivados de glutamato, ou metabólitos, análogos de glutamato ou misturas dos mesmos, para modular a qualidade dos ossos, assim como composições para uso no tratamento.
BR0214364-0A 2001-11-23 2002-11-22 Métodos para obter melhorada qualidade dos ossos de um vertebrado e para modular a qualidade dos ossos de um vertebrado, uso de glutamato, derivados de glutamato, ou metabólitos, análogos de glutamato ou misturas dos mesmos, e, método para inibir, prevenir ou aliviar a degradação da estrutura óssoa ou enfraquecimento óssea em um vertebrado BR0214364A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0103932 2001-11-23
SE0104385A SE520842C2 (sv) 2001-11-23 2001-12-21 Användning av glutamat, glutamatderivat, glutamatmetaboliter eller glutamatanaloger för att framställa en sammansättning för behandling av osteoporos
SE0201713A SE0201713D0 (sv) 2001-11-23 2002-06-06 New methods and use III
PCT/SE2002/002123 WO2003043626A1 (en) 2001-11-23 2002-11-22 Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis

Publications (1)

Publication Number Publication Date
BR0214364A true BR0214364A (pt) 2004-10-26

Family

ID=27354772

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214364-0A BR0214364A (pt) 2001-11-23 2002-11-22 Métodos para obter melhorada qualidade dos ossos de um vertebrado e para modular a qualidade dos ossos de um vertebrado, uso de glutamato, derivados de glutamato, ou metabólitos, análogos de glutamato ou misturas dos mesmos, e, método para inibir, prevenir ou aliviar a degradação da estrutura óssoa ou enfraquecimento óssea em um vertebrado

Country Status (14)

Country Link
US (2) US8603981B2 (pt)
EP (1) EP1446112B1 (pt)
JP (1) JP4447913B2 (pt)
KR (1) KR100961291B1 (pt)
CN (1) CN100531731C (pt)
AU (1) AU2002366111B2 (pt)
BR (1) BR0214364A (pt)
CA (1) CA2467676C (pt)
DK (1) DK1446112T3 (pt)
ES (1) ES2431085T3 (pt)
MX (1) MXPA04004904A (pt)
PT (1) PT1446112E (pt)
SE (1) SE0201713D0 (pt)
WO (1) WO2003043626A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1745791B1 (en) 2003-05-07 2013-06-26 Osteologix A/S Treating cartilage/bone conditions with water-soluble strontium salts
RU2360671C2 (ru) * 2003-07-01 2009-07-10 Эссентис Аб Применение альфа-кетоглутаровой кислоты для лечения недостаточности питания или состояния с высоким уровнем глюкозы в плазме
SE0301947D0 (sv) * 2003-07-01 2003-07-01 Gramineer Internat Ab New method and uses
US7335686B2 (en) * 2003-10-20 2008-02-26 Council Of Scientific And Industrial Research Method and composition for treating osteoporosis
CA2557324C (en) 2004-02-26 2012-10-16 Osteologix A/S Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
PL368573A1 (en) * 2004-06-17 2005-12-27 Sgp & Sons Ab Pharmaceutical compound influencing growth and mineralization processes in the axial and the appendicular skeleton as well as bone diseases of mature years among humans and animals as well as application of the pharmaceutical compound in the process of growth and mineralization of axial and appendicular skeleton and bone diseases of mature years among humans and animals
PL370937A1 (pl) * 2004-10-29 2006-05-02 Sgp & Sons Ab Preparat żywieniowy i/lub farmaceutyczny do stosowania w profilaktyce i leczeniu niedoborów wchłaniania mikroelementów z przewodu pokarmowego oraz zastosowanie preparatu farmaceutycznego jako czynnika stymulującego wchłanianie mikroelementów z przewodu pokarmowego do krwi
PL371081A1 (pl) * 2004-11-08 2006-05-15 Sgp & Sons Ab Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt
US20110105617A1 (en) * 2005-01-11 2011-05-05 Sgp & Sons Ab Method for treatment of neoplastic diseases with alpha-keto glutarate and/or salts thereof
PL372183A1 (pl) * 2005-01-11 2006-07-24 Sgp & Sons Ab Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego
CN101309678B (zh) * 2005-11-15 2011-04-20 安特瑞斯公司 用于与软骨损伤有关的应用的药物
CN103491804A (zh) * 2011-04-18 2014-01-01 雀巢产品技术援助有限公司 具有α-HICA 和二十碳五烯酸的营养组合物
CN108478551A (zh) * 2011-11-21 2018-09-04 埃默斯医疗股份有限公司 用于治疗糖尿病和相关病症的方法和组合物
CN102805857B (zh) * 2012-08-27 2014-07-02 北京紫萌同达科技有限公司 一种复方氨基酸(15)双肽(2)注射液的制备方法
CN105231038A (zh) * 2015-09-23 2016-01-13 华南农业大学 α-酮戊二酸在制备猪饲料添加剂方面的应用
EP3490971A4 (en) * 2016-08-01 2020-02-26 Filament Biosolutions Inc. METHODS OF TREATING AND PREVENTING SIDE EFFECTS OF CANCER TREATMENT
CN110935005A (zh) * 2019-11-19 2020-03-31 宁波大学 一种丙谷二肽的新用途
CN111820330A (zh) * 2020-07-17 2020-10-27 禹城保立康生物饲料有限公司 一种提高哺乳仔猪发育的母猪饲料
KR20250123009A (ko) * 2024-02-06 2025-08-14 주식회사 메타센테라퓨틱스 아연 트랜스포터 액티베이터 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668295A (en) * 1985-04-25 1987-05-26 University Of Dayton Surgical cements
US5310768A (en) * 1987-10-29 1994-05-10 Ab Erik Vinnars Method for improving the glutamine content in skeletal muscle and composition therefore
JPH01216924A (ja) 1988-02-24 1989-08-30 Ajinomoto Co Inc 肝障害治療剤
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
JPH04164028A (ja) 1990-02-19 1992-06-09 Miwon Co Ltd グルタミン酸モノナトリウムを主成分とする疲労快復剤およびその使用方法
JP2702322B2 (ja) 1991-08-08 1998-01-21 フジックス株式会社 活性アミノ酸カルシウム、およびそれを含有する飲料、ならびにその製造方法
JP3551149B2 (ja) 1992-03-24 2004-08-04 味の素株式会社 易吸収性ミネラル含有組成物及びそれを含有する飲食品
US5646187A (en) * 1992-05-20 1997-07-08 Ab Erik Vinnars Use of alpha-ketoglutarate
JP2964290B2 (ja) 1992-08-25 1999-10-18 雪印乳業株式会社 ミネラル吸収促進剤
US5380934A (en) 1992-10-29 1995-01-10 Kyowa Hakko Kogyo Co., Ltd. Process for producing alanylgutamine
DE69330595T2 (de) 1992-11-25 2002-05-23 Ajinomoto Co., Inc. Zubereitungen und Nahrungsmittel enthaltend Mineralien und Poly-gamma-Glutaminsäure
US5849695A (en) * 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
SE9303691D0 (sv) 1993-11-09 1993-11-09 Gramineer Ab New beverage
CN1060336C (zh) * 1995-12-05 2001-01-10 孔彦平 一种防治钙质缺损的药物及其制备方法
US5817329A (en) * 1997-02-28 1998-10-06 Gardiner; Paul T. Nutritional supplement for increased muscle size and strength for body builders
NL1014380C2 (nl) 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.

Also Published As

Publication number Publication date
ES2431085T8 (es) 2014-01-03
US9233088B2 (en) 2016-01-12
JP2005518353A (ja) 2005-06-23
EP1446112A1 (en) 2004-08-18
AU2002366111B8 (en) 2003-06-10
PT1446112E (pt) 2013-10-21
CA2467676A1 (en) 2003-05-30
ES2431085T3 (es) 2013-11-25
AU2002366111B2 (en) 2007-06-28
EP1446112B1 (en) 2013-07-17
MXPA04004904A (es) 2005-04-11
KR100961291B1 (ko) 2010-06-04
JP4447913B2 (ja) 2010-04-07
US20140194521A1 (en) 2014-07-10
SE0201713D0 (sv) 2002-06-06
US8603981B2 (en) 2013-12-10
DK1446112T3 (da) 2013-10-07
HK1071059A1 (en) 2005-07-08
WO2003043626A1 (en) 2003-05-30
AU2002366111A1 (en) 2003-06-10
CN100531731C (zh) 2009-08-26
CA2467676C (en) 2011-07-12
KR20050044589A (ko) 2005-05-12
US20040259766A1 (en) 2004-12-23
CN1602190A (zh) 2005-03-30

Similar Documents

Publication Publication Date Title
BR0214364A (pt) Métodos para obter melhorada qualidade dos ossos de um vertebrado e para modular a qualidade dos ossos de um vertebrado, uso de glutamato, derivados de glutamato, ou metabólitos, análogos de glutamato ou misturas dos mesmos, e, método para inibir, prevenir ou aliviar a degradação da estrutura óssoa ou enfraquecimento óssea em um vertebrado
Bell et al. Intraoral widening and lengthening of the mandible in baboons by distraction osteogenesis
Kargi et al. Effect of steroids on edema, ecchymosis, and intraoperative bleeding in rhinoplasty
ATE293883T1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
Hsia et al. Osteophytes and fracture calluses share developmental milestones and are diminished by unloading
DE69930252D1 (de) Verwendung von tetracyclinen zur behandlung von störungen der meibomschen drüsen
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
EP0950417A3 (en) Treatment of skeletal disorders
BR0314308A (pt) Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto
CY1111471T1 (el) Μεθοδοι για τον καθαρισμο trans-(-)-δ9-τετραϋδροκανναβινολης και trans-(+)-δ9 τετραϋδροκανναβινολης
ATE282413T1 (de) Verwendung von tempol zur behandlung von essentiellem hochdruck
PT881908E (pt) Utilizacao dos factores de crescimento de fibroblasto para estimular o crescimento osseo
BR9503406A (pt) Formulaçoes farmacêuticas adaptadas para inhibir para perda de osso em um ser humano
ATE239474T1 (de) Verwendung von levobupivacain
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
BRPI0407178A (pt) Composição farmacêutica osteogênica
Kankate et al. Percutaneous plating of the low energy unstable tibial plateau fractures: a new technique
ATE266396T1 (de) Zubereitung und verwendung von rar antagonisten zur forderung der chondrogenese
Çelik et al. Nasal reconstruction using both cranial bone and ear cartilage
KR970701044A (ko) 콜린에스테라제 활성제
BR0315609A (pt) Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
DK0871446T3 (da) Anvendelse af eliprodil til fremstilling af et lægemiddel til behandling af ischaemiske sygdomme i nethinden eller den optiske nerve
BR9911237A (pt) Novo uso de um derivado de piridazinona
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A23K 1/16, A23L 1/305, A61K 31/198, A61K 19/00, A61P 43/00

Ipc: A23K 1/16 (2011.01), A23L 1/305 (2011.01), A61K 31

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/194 (2006.01), A23L 33/175 (2016.01), A61K